The REAL Reason For the Growth of ADHD in the US
 

http://www.genengnews.com/news/bnite..._TO_NEWSML.xml

Breaking News

Excerpts:


The Current Marketed Psycho Stimulants Quickly and Effectively Alleviate
ADHD Symptoms

Business Implications

-- Currently, the most common pharmacological treatments for adult ADHD are
psychostimulants. The exact mechanisms by which these agents improve
symptoms are not well understood, but their use is substantial and
effective: physicians interviewed state that 80-90% of their patients
treated with either methylphenidate or amphetamine experience a reduction in
ADHD symptoms.

-- Because psychostimulants are efficacious, there is little demand for
novel mechanisms to treat adult ADHD. Shire's NRP-104, a pro-drug of
amphetamine, is the most exciting drug in development for ADHD, and we
expect it to achieve blockbuster status. This drug, expected to launch in
2010, will offer the efficacy of amphetamine without the potential for
abuse. Overall, Shire will launch four new ADHD agents by 2010, establishing
itself as the market leader.

-- Growth in the ADHD market will be fuelled by several favourable factors,
including physician adoption of a broader definition of the disease, a low
rate of misdiagnosis compared with other psychiatric disorders, and an
increase in the number of adults who self-refer themselves for treatment. In
addition, a growing selection of drugs approved for treatment of adult ADHD,
a higher rate of compliance, and an increase in the number of days treated
will drive growth in this therapeutic market.

Contents Include:

-- Introduction

-- Overview of Adult ADHD

-- Prevalence of Adult ADHD

-- Targets for ADHD Drug Development

-- Current Therapies for ADHD

-- Promising Emerging Therapies

-- Factors Driving and Restricting Growth in the Adult ADHD Market

-- Outlook for the Adult ADHD Market

-- Appendix

Companies Mentioned:

-- Alza

-- Boehringer Ingelheim

-- Cephalon

-- Eli Lilly

-- GlaxoSmithKline

-- Novartis

-- Shire

-- UCB's Metadate CD

-- Wyeth